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Abstract
Background: There is little research on parents’ experiences of suspected adverse drug reactions in their children and hence
little evidence to guide clinicians when communicating with families about problems associated with medicines.
Objective: To identify any unmet information and communication needs described by parents whose child had a suspected
adverse drug reaction.
Methods: Semi-structured qualitative interviews with parents of 44 children who had a suspected adverse drug reaction
identified on hospital admission, during in-patient treatment or reported by parents using the Yellow Card Scheme (the UK
system for collecting spontaneous reports of adverse drug reactions). Interviews were conducted face-to-face or by
telephone; most interviews were audiorecorded and transcribed. Analysis was informed by the principles of the constant
comparative method.
Results: Many parents described being dissatisfied with how clinicians communicated about adverse drug reactions and
unclear about the implications for their child’s future use of medicines. A few parents felt that clinicians had abandoned
their child and reported refusing the use of further medicines because they feared a repeated adverse drug reaction. The
accounts of parents of children with cancer were different. They emphasised their confidence in clinicians’ management of
adverse drug reactions and described how clinicians prospectively explained the risks associated with medicines. Parents
linked symptoms to medicines in ways that resembled the established reasoning that clinicians use to evaluate the
possibility that a medicine has caused an adverse drug reaction.
Conclusion: Clinicians’ communication about adverse drug reactions was poor from the perspective of parents, indicating
that improvements are needed. The accounts of parents of children with cancer indicate that prospective explanation about
adverse drug reactions at the time of prescription can be effective. Convergence between parents and clinicians in their
reasoning for linking children’s symptoms to medicines could be a starting point for improved communication.
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Introduction
Like all patients, children are at risk of adverse drug reactions
(ADRs). We define an ADR as a ‘‘harmful or unpleasant reaction,
resulting from an intervention related to the use of a medicinal product, which
predicts hazard from future administration and warrants prevention or specific
treatment, or alteration of the dose regimen, or withdrawal of the product [1].’’
Our use of the term ADR in this paper also follows that of the
World Health Organisation and UK Medicines and Healthcare
Products Regulatory Agency (MHRA), in that our focus was on
reactions which occurred at normal therapeutic doses [2,3] and
were suspected by clinicians or parents to be related to the action
of a medicine. ADRs may be distinguished from adverse medical
events, which are untoward occurrences that may be present
during medicinal treatment but which are not necessarily related
to the action of the medicine, and may include errors in diagnosis,
treatment and management that result in harm to the patient [1].
Evidence suggests that patients are generally poorly informed
about medicines and the systems to ensure drug safety [4,5]. The
literature on communicating about medicines indicates the
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advantages of involving patients in open discussions about the
potential benefits and risks of medicines at the time these are
prescribed [6–11], the importance of such discussions for informed
consent and decision making [6,8,10–13], and the value of
supplementary verbal and written information tailored towards the
needs of patients [7–9,14]. The literature also highlights the
complexities involved in communicating with patients about the
uncertainties associated with medicines [8,11–13,15] and describes
the relative merits of different methods of presenting information
on risk and uncertainty, such as the use of numerical probabilities
and frequencies [16,17], and who should communicate informa-
tion about risks of medicines [18].
This growing body of literature provides valuable general
guidance for practitioners in communicating openly with patients
about medicines. Providing patients with information about
medicines is important. However, there are also concerns that
informing patients about ADRs prospectively can induce expec-
tations that leave patients more susceptible to experiencing ADRs
and less likely to adhere to treatment [19]. Furthermore, untoward
events during an illness may also be misattributed to medicines by
patients and others [20].
The promotion of treatment adherence has driven much
research and theory on beliefs and communication about
medicines [21]. Evidence and theory suggest that patient
adherence to a medicine is influenced by their beliefs [22–24].
The necessity-concerns framework [25] proposes that uptake and
adherence to particular medicines is influenced by how patients
evaluate the need for that medicine relative to their concerns
about ADRs. At a more general level, patients’ evaluations are also
thought to be influenced by cultural beliefs, such as beliefs that
medicines are harmful or overused [26]. More recently, attention
has focussed on the concept of perceived sensitivity to the effects of
medicines, that is, how responsive or susceptible patients perceive
themselves to be to the effects of medicines, and how these
perceptions of sensitivity influence patients’ concerns about
potential ADRs, reporting of ADRs and medication adherence
[19,27].
While efforts to optimise treatment adherence have driven
much of the work on beliefs and communication about medicines
[21], and optimising adherence is an important objective, less
attention has focussed on enhancing communication about
medicines as an important goal in its own right. In particular,
little attention has been paid to the lessons that can be learnt from
patients’ accounts of experiencing ADRs and how these lessons
can contribute to enhancing communicating about medicines and
adherence. Moreover, little is currently known about the particular
experiences and needs of child patients and their parents following
the occurrence of a suspected ADR. Research has examined
parents’ perceptions of risks associated with child vaccines, but this
has focussed on ways to promote adherence to vaccine schedules,
rather than on parents’ experiences of care in the aftermath of a
suspected ADR [28–32]. Bellaire et al report that children with
multiple ADRs following antibiotic treatment may experience
lower health-related quality of life (HRQL) as perceived by
parents, than healthy children or those with only one ADR [33].
However, interpretation of these findings is difficult as children
with multiple ADRs in this study had significantly more co-
morbidity than the other groups, so non-ADR related factors
cannot be excluded as an explanation for the lower HRQL among
the multiple ADR group [33]. Bellaire et al also describe anecdotal
comments from participating parents suggesting that children’s
ADRs are a significant source of concern for parents [33].
Evidence that members of the public are particularly concerned
about children’s medicines comes from a study comparing lay
people’s responses to hypothetical scenarios involving medicines
for child or adult patients. Respondents perceived the risks of
ADRs to be more severe and reported that they would be less
likely to take (or give) a medicine when the recipient was a child
rather than an adult [9]. Adult patients receiving treatment for
acute conditions and admitted to hospital with an ADR were
frustrated and frightened by the experience [34], yet the situation
of parents of child patients is likely to be further complicated by
the frequent prescribing of unlicensed and off-label drugs in
paediatrics [35–37] and by parents’ distinctive role in caring for
their children [38,39].
Clinicians are encouraged to consider ADRs during the
evaluation of every patient they see. There are established ways
to assess the possibility that a drug has caused a harmful or
unpleasant event. Although these causality assessments differ in
their details, they contain some common elements. For example,
the widely used Naranjo scale [40] includes questions such as ‘‘Did
the adverse event appear after the suspected drug was adminis-
tered?’’, ‘‘Did the adverse reaction reappear after the drug was
readministered?’’ and ‘‘Are there alternative causes (other than the
drug) that could on their own have caused the reaction?’’. These
questions should be part of the clinical reasoning that clinicians use
when they encounter a child with a potential ADR. The questions
may be implicit or explicit but they are available to the clinician
during their assessment. In principle, these questions are also
available to the clinician when structuring their communication
with children and their parents. It is unclear whether clinicians
share their reasoning with parents and children.
In summary, there is a need to consider communication about
ADRs as an important objective in its own right and in the context
of optimising adherence. There are particular concerns that seem
to surround children’s medicines. Clinicians have access to
structured approaches to dealing with suspected ADRs. Never-
theless, little is known about the experiences of parents when their
child has had a suspected ADR. This means that clinicians have
little evidence to guide them when communicating with families in
the aftermath of a suspected ADR.
To inform the management of communication about ADRs in
children we investigated parents’ experiences of suspected ADRs
in their child. Our focus was to identify any unmet psychological,
information and communication needs described by parents.
Given the absence of previous research in this area, we designed
our qualitative study, ADRIC-QUAL, to explore all aspects of
parents’ experiences and views, from their accounts of commu-
nication at the point at which medicines were prescribed, to their
views about the implications of ADRs for their child’s future health
[41].
Methods
Ethics statement
A UK National Health Service research ethics committee
approved the study (Northwest 3 Research Ethics Committee 08/
H1002/7). All participants gave written informed consent.
Sampling, setting and recruitment
As recommended in qualitative research when there has been
little previous research on a topic, we sampled for maximum
variation [42,43]. We used two sampling routes to ensure diversity
in terms of ADR type and severity, and clinical speciality. The first
route comprised two cohort studies. These were part of the
Adverse Drug Reactions in Children (ADRIC) programme
conducted at a regional paediatric hospital in the UK [44]. In
particular, two studies within the ADRIC Programme (ADRIC1
Communication about Adverse Drug Reactions
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and ADRIC2) investigated the prevalence of suspected ADRs
among all patients aged less than 17 years; ADRIC1 focussed on
patients with an unplanned hospital admission, while ADRIC2
focussed on patients admitted for 48 hours or more. ‘ADRIC
families’ were eligible for ADRIC-QUAL if they could be
approached about the study before discharge. They were not
eligible if the family were experiencing pronounced distress or
there were child protection concerns. Clinicians, hospital manag-
ers and the Ethics Committee concurred that approaching families
in the latter two groups could complicate an already sensitive
clinical situation and could not be justified for this research
project. Treating clinicians initially introduced ADRIC-QUAL
and interviewers subsequently provided interested families with
more detailed information and contacted families post-discharge
to arrange the interview.
We suspected ADRIC patients’ ADRs were probably at the
more severe end of the spectrum so we used a second sampling
route, the Yellow Card Scheme [3], in order to maximise
variability [42,43]. Using the Yellow Card Scheme also enabled
us to access a sub-sample of parents without the potential influence
of clinician gate-keeping (in route 1 there was a possibility that
treating clinicians may have declined to invite eligible ADRIC
parents to participate, for example, due to reluctance to discuss
ADRs with parents or because of perceived difficulties in the
parent-clinician relationship). The Yellow Card Scheme is a
national drug surveillance system which allows patients and
families (as well as clinicians) to spontaneously report suspected
ADRs directly to the UK competent authority for medicines
approval and monitoring, the MHRA. Initially, the MHRA sent
study invitation letters to all parents who had submitted a Yellow
Card (YC) on behalf of a child under 17 years. However, in the
first six months most parents were reporting suspected ADRs
linked to vaccines, so thereafter only parents submitting YCs about
non-vaccine related ADRs were sent letters. The letters outlined
the study and invited parents to return a reply slip to the ADRIC-
QUAL team if they wished to participate. The ADRIC-QUAL
interviewer then telephoned parents to further explain the study
and arrange an interview.
Sampling ran in parallel with data analysis, and was discontin-
ued when saturation on the main analytical categories was reached
[45].
Interviews
Interviewers explained their independence from clinical teams
and the MHRA before all interviews. JA and HH conducted face
to face interview with ADRIC parents. YC parents resided across
the UK, so JA, HH and ES conducted telephone interviews with
them. Interviews were semi-structured and informed by a topic
guide that contained prompts about families’ experiences of: signs
and symptoms in their child and how they linked these to a
medicine; awareness of suspected ADRs; written and verbal
communication with clinicians and views about the implications of
ADRs for children (see Table S1 ‘Parents’ generic interview
guide’). Interviewers tailored their questions to ensure interviews
were conversational, and previously unanticipated topics were
explored as interviewing and analysis progressed.
All audio-recorded interviews were transcribed. Transcripts
included indicators of hesitation, repetition, dysfluency and sub-
verbal vocalisations and were checked by the interviewer who
removed all identifying details before analysis. Field notes were
also recorded detailing the interview context, such as the setting of
the interview, and observations and reflections on the interview
process, including participants’ interaction, demeanour and
significant non-verbal behaviour.
Analysis
Researchers point to the value of flexibility in inductive research
and the importance of ensuring that the aims of a particular study
guide the methods, rather than the reverse [46–49]. In this study,
our overarching aim was to inform practice. While our analysis
drew on methods associated with grounded theory such as
constant comparison [41,45,50–54], we selected and applied these
methods to fit with our focus on informing practice and the
criterion of catalytic validity, whereby the findings should not
merely describe, but have the potential to inform research and
practice [55,56]. Our orientation to the analysis was broadly
interpretive that is, while our focus was parents’ experiences, we
did not simply take their accounts at face value, rather we
considered how parents constructed their experiences and what
was latent or deemphasised in their accounts, as well as the
manifest content [57–60].
JA led the analysis and development of the coding framework in
a process that had both inductive and deductive aspects. She read
transcripts several times to develop analytic categories regarding
the content and meaning of particular transcript sections. To avoid
a fragmented or decontextualised analysis [61] and ensure that the
analytical categories and developing analysis were consistent with
participants’ overall stances in their interviews, JA referred to the
interviews as a whole [59]. This is important as the meaning of a
transcript section might only become apparent by considering a
participant’s narrative as it develops over an entire interview.
Similarly, JA also referred to the field notes during the analysis to
prompt her recollection of contextual and process aspects of the
interview and use these to help interpret the transcript sections.
For example, field note reflections on a participant’s interaction
and the emotional ‘tone’ of the interview assisted in interpreting
sections of transcript that might otherwise be ambiguous or
misinterpreted. BY and MT supported the analysis by reading a
sample of the transcripts and by ‘testing’ and developing the
analysis through periodic discussion with JA. All three analysts
compared within and between transcripts, and iterated between
developing analytical categories and new data [41,51–
54,61,62,63]. We did not use a qualitative data analysis software
to assist the analysis, as we found the functions in Microsoft Word
adequate [64]. However, we employed a number of methods that
are recommended to help ensure rigour in the analysis of
qualitative data. We used respondent validation, whereby we
discussed the emerging analysis with later participants [41,62]. We
also attended to exceptional or ‘deviant’ cases, that is, cases that
were untypical either because of the patient demographic or
disease profile or because of the families’ experiences, and
examined how differences between these and more typical cases
could inform the data analysis [51–54,62,63]. Finally, we
scrutinized the quality of the developing analysis according to its
coherence and, as noted above, its potential to influence practice, a
process that was assisted by discussion among all authors [62,65].
This multi-disciplinary investigator triangulation aimed to ensure
the quality and clinical relevance of the analysis [66,67]. We
present brief data extracts in the main text of the results to
illustrate key findings and supplement these with data extracts in
boxes to evidence our interpretations of parents’ accounts.
Extracts are italicised and coded ‘‘A’’ (ADRIC parents) or ‘‘YC’’
(Yellow Card parents). Omitted speech is indicated by […];
explanatory text by [text].
Communication about Adverse Drug Reactions
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Results
Participants
We conducted audiorecorded interviews with 45 parents of 44
children (41 mothers, four fathers). Of the 27 ADRIC families, 10
were recruited via ADRIC1 and 17 via ADRIC2. A total of 21
ADRIC2 families were approached to participate: three declined
because of the child’s repeated hospital admissions, and one further
family was interviewed but declined to be audiorecorded. We were
unable to record the number of ADRIC1 families who were
approached to participate in ADRIC-QUAL by treating clinicians.
Fifty-four YC families were sent MHRA invitation letters. Details of
non-responders are not available, but of 21 who replied, we had
audiorecorded interviews for 17. Of the four remaining YC parents,
one could not be contacted and interviews with three were not
audiorecorded due to equipment failure. Therefore, a total of four
interviews had not been audiorecorded. Our only record of these
was the fieldnotes made by the researchers after the interviews had
taken place. Because these fieldnotes were considerably less detailed
than the transcribed recordings and did not contain verbatim
speech, we did not consider the fieldnotes to be equivalent to the
transcribed recordings or treat them as such in the analysis.
However, our review of the fieldnotes for the non-audiorecorded
interviews indicated that they were consistent with the findings from
the transcribed interviews.
Interviews lasted approximately 60 minutes (ranging from 20 to
100 minutes) and were conducted between 2–56 weeks after the
suspected ADR. Three ADRIC parents were interviewed in private
rooms in the hospital; the remainder were interviewed in their
homes. All YC parents were in their homes during the telephone
interviews. The Index of Multiple Deprivation scores of Yellow Card
participants indicated less deprivation among this group than the
ADRIC participants. Table 1 shows demographic characteristics for
participants. To indicate the clinical context of each child, Table 1
also shows (as reported by parents) the type of medicines children
had taken and the body system affected by the ADR. Where
relevant, hospitalisation details and the body system affected by any
underlying conditions that children had are also shown. Of the 26
ADRIC children whose suspected ADRs were classified using the
Liverpool Causality Assessment Tool as part of the ADRIC 1 and 2
studies [68], three (11%) were deemed unlikely to have had an ADR,
four (15%) were possible ADRs, 11 (41%) were probable and eight
(30%) were definite. Data on ADR classifications are not available
for one (4%) remaining ADRIC child or for the YC children.
The format in which we present our findings broadly reflects the
main categories that we developed during the course of the
analysis. We first describe parents’ accounts of communication
about medicines at the time of prescription and how they first
became aware that their child’s symptoms might be linked to a
medicine. We then describe parents’ accounts of seeking help for
their child’s symptoms and their experiences of communication
with clinicians when an ADR came to be suspected, the
implications this communication had for parents’ sense of
involvement in their child’s care, their perceptions regarding
how their child’s future care needs would be addressed, and how
the experience of a suspected ADR influenced parents’ views
about children’s medicines. Finally, we present parents’ sugges-
tions regarding how communication could be enhanced to better
address their needs and those of their child.
Little explanation of the risks of medicines at the time
they were prescribed
Most parents indicated that clinicians tended not to explain the
risks of medicines when the medicines were prescribed: ‘‘No side-
effects were made known to me’’ (YC5). Parents explained how
clinicians focussed on other issues, such as explaining their child’s
condition and the importance of medicines or surgery in treating
the condition: ‘‘They [the surgeons] don’t discuss the drugs; they discuss
the surgery itself’’ (A23). If the risks of medicines were discussed, it
was often at a time when parents struggled to absorb information,
such as shortly before a child was due to be anaesthetised: ‘‘On the
day your child is being operated on or when the anaesthetist comes up you are
not thinking of anything other than […] what’s going to happen in the
operation’’ (A16).
Parents also reported difficulties with written information about
medicines and potential ADRs. They either did not receive these
documents: ‘‘No information leaflet was given to me’’ (YC5); ‘‘You only get
the bottle from the doctor don’t you?’’ (A1) or found them hard to engage
with because the documents were too lengthy or did not seem
relevant to their own child: ‘‘I did a carefree glance [at the patient
information leaflet] and chucked it’’ (YC13). A key exception to these
accounts of poor communication was the parents of children with
cancer , who described how clinicians provided comprehensive
information about the types of reactions that medicines could
cause and emphasised how clinicians carefully timed and paced
their explanations so that parents could absorb the information:
‘‘They explained things in little bits so it sinks in […] they did say he would
become neutropenic’’ (A6). Parents of children with cancer also
commented on how they were regularly asked about any medicine
related difficulties their children were experiencing.
How parents become aware that their child may be
experiencing an ADR
Parents usually described an initial period in which they began
to suspect something was wrong with their child based on a wide
collection of physical symptoms and changes in behaviour that
were ‘out of the ordinary’. With the exception of parents of
children whose suspected ADR had first been identified by
clinicians or whose children had cancer, parents initially tended to
attribute symptoms to trivial causes such as minor illness, injury, or
changes in their child’s life or environment. It was only when
symptoms worsened that parents became concerned: ‘‘His colour
dropped and his breathing went a bit funny and he started to panic, that
worried me’’ (A25) and they started to consider possible links to
medicines.
Parents reported how they linked their child’s symptoms to a
medicine when they noticed patterns in their child’s symptoms,
such as a temporal association between giving a medicine and the
onset of symptoms: ‘‘It just seems strange to me that she had it [the
medicine] and then straight away like she got that temperature’’ (A10); ‘‘The
bottle would be finished, and the next day she would come out in a rash’’ (A1);
‘‘It’s too much of a coincidence […] she had a needle and then that happened.
She had a vaccination and then she had that’’ (A8). Some parents also
noticed how their child’s symptoms receded between doses: ‘‘She
wasn’t sick all night and then the next two times she had the Penicillin she
threw up near enough ten minutes, fifteen minutes later’’ (A5); ‘‘He was off it
[the medicine] for a couple of days. And then on the Sunday we noticed that
his behaviour wasn’t as bad’’ (YC14); ‘‘I noticed a difference […] when she
was having it [the medicine] and when she wasn’t having it […] she started
on it again and then we noticed the symptoms within a few days again of
having it’’ (YC7). The absence of an alternative explanation for
their child’s symptoms also influenced parents’ attributions about
their child’s suspected ADR: ‘‘She came out of hospital when she was
born and she hasn’t been anywhere. She hasn’t [had] nothing- nothing like
foreign in her body at all, until she went for that vaccination’’ (A10); ‘‘[The
medicine] is the only thing she’s had and she hadn’t had a cold or been ill
before it’’ (YC10).
Communication about Adverse Drug Reactions
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Table 1. Children’s demographic characteristics, medicine type and ADR information.
ID Age1 Gender
Ranked
IMD
scores2
Type of drug
associated
with suspected
ADR
Body system
affected by
suspected ADR
Severity
score3
Whether suspected ADR
contributed to
hospitalisation/prolonged
inpatient stay
Underlying condition
by body system
A1 3–5 Female 403 Antibiotics Skin and mucous
membranes
3 Yes (contributed towards
admission)
Respiratory
A2 12+ Male 10787 NSAID Musculoskeletal 3 Yes (reason for admission) Musculoskeletal
A3 3–5 Male 306 Corticosteroids,
Cytotoxics
Haematological 3 Yes (reason for admission) Haematological
A4 12+ Female 2482 Cytotoxics Gastrointestinal 3 Yes (reason for admission) Haematological
A5 0–2 Female 12821 Antibiotics Skin and mucous
membranes
3 Yes (reason for admission) Respiratory
A6 0–2 Male 1574 Cytotoxics Haematological 3 Yes (reason for admission) Haematological
A7 0–2 Male 15485 Corticosteroids,
Cytotoxics
Haematological,
immune system
3 Yes (reason for admission) Haematological
A8 3–5 Female 383 Vaccines Skin and mucous
membrane
3 Yes (reason for admission) None
A9 6–11 Male 6091 Corticosteroids Immune 3 Yes (reason for admission) Musculoskeletal
A10 0–2 Female 12223 Vaccines Immune Infection Missing Missing Gastrointestinal
A11 6–11 Female 16778 Antibiotics Skin and mucous
membranes
1 No (inpatient stay not
prolonged)
Musculoskeletal, nervous,
respiratory, gastrointestinal,
skeletal
A12 3–5 Female 271 Antiepileptic Hepatic 3 No (inpatient stay not
prolonged)
Musculoskeletal, nervous,
gastrointestinal
A13 0–2 Male N/A Antibiotics Skin and mucous
membranes
3 No (inpatient stay not
prolonged)
Musculoskeletal,
gastrointestinal, nervous
A14 6–11 Male 19865 Opioid analgesia Nervous 3 No (inpatient stay not
prolonged)
Gastrointestinal
A15 12+ Female 24299 Opioid analgesia+other
post-operative analgesia
Nervous 3 No (inpatient stay not
prolonged)
Musculoskeletal
A16 0–2 Female 24447 Opioid analgesia Skin and mucous
membranes
3 No (inpatient stay not
prolonged)
Gastrointestinal
A17 12+ Male 108 Opioid analgesia Gastrointestinal 1 No (inpatient stay not
prolonged)
Gastrointestinal
A18 12+ Male N/A Antibiotics Manifestation was
flushing of skin but
underlying cause was
immune
3 No (inpatient stay not
prolonged)
Musculoskeletal, skin and
mucous membranes, renal,
gastrointestinal, metabolic
A19 0–2 Male 18461 Antibiotics Manifestation was
flushing of skin but
underlying cause was
immune
3 No (inpatient stay not
prolonged)
Gastrointestinal
A20 6–11 Female 14971 Drugs used in status
epilepticus
Nervous 1 No (inpatient stay not
prolonged)
Gastrointestinal
A21 12+ Male 19823 Opioid analgesia Gastrointestinal 3 No (inpatient stay not
prolonged)
Musculoskeletal
A22 6–11 Male 29022 Opioid analgesia Respiratory 1 No (inpatient stay not
prolonged)
Musculoskeletal, nervous
A23 3–5 Male 5171 Opioid analgesia Gastrointestinal 3 No (inpatient stay not
prolonged)
Cardiovascular
A24 12+ Male N/A Corticosteroid Cardiovascular 5 No (inpatient stay not
prolonged)
Haematological
A25 6–11 Male 26028 Opioid analgesia Nervous 3 No (inpatient stay not
prolonged)
Musculoskeletal, nervous
A26 12+ Female 11667 Drugs affecting the
cardiovascular system
Nervous 3 No (inpatient stay not
prolonged)
Musculoskeletal,
cardiovascular
A27 6–11 Female 24071 Antibiotics; Non-opioid
analgesia
Skin and mucous
membranes
3 No (inpatient stay not
prolonged)
Respiratory
YC1 12+ Male 32210 Immunological
products and vaccines
Endocrine N/A N/A None
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Outside oncology, parents also spoke about the information
sources that they drew on when making attributions about their
child’s symptoms. This included their personal experience with
medicines, media coverage of problems with medicines and the
concerns of friends and family: ‘‘A lot of friends decided against it [the
human papilloma virus vaccine] because it was a new vaccine’’ (YC3).
Information on the Internet could be a source of considerable
anxiety for parents: ‘‘I was on the Internet looking at all kinds of, I was
beside myself, comas and everything’’ (A8).
With few exceptions, parents were critical about ADR
management and communication
In a context in which parents sometimes described being
overwhelmed with fear about their child’s symptoms: ‘‘I was at my
wits end. All sorts were going through my mind’’ (A2), parents’
communication needs could be extensive. However, parents’
accounts indicated that clinicians’ communication about a child’s
suspected ADR was often poorly matched to parents’ needs: ‘‘They
don’t communicate with you as well as they should do, by my opinion’’ (A23).
Parents described a lack of communication that might help them
understand what was happening to their child while his or her
symptoms were being assessed and how clinicians were managing
their child’s symptoms: ‘‘No-one actually ever said why it [the
hallucination] was happening, the nurses thought it was a bit funny, they
all kept coming over to see him and laughing with him sort of thing’’ (A14).
They reported communication as being contradictory and poorly
coordinated, with some clinicians attributing the child’s symptoms
to a medicine, while other clinicians attributed the same symptoms
to different causes: ‘‘The first man said it was herpes […] and then the
nice doctor downstairs said, ‘No, this is a reaction to Penicillin’’’ (A5).
Parents remarked that the way in which clinicians managed and
communicated uncertainty surrounding an ADR’s identification
did little to reassure them: ‘‘I was saying ‘well, when she goes home, can I
Table 1. Cont.
ID Age1 Gender
Ranked
IMD
scores2
Type of drug
associated
with suspected
ADR
Body system
affected by
suspected ADR
Severity
score3
Whether suspected ADR
contributed to
hospitalisation/prolonged
inpatient stay
Underlying condition
by body system
YC2 12+ Male 17251 Drugs used for attention
deficit disorder
Neurological N/A N/A Mental health
YC3 12+ Female 20387 Immunological products
and vaccines
Haematological N/A N/A None
YC4 12+ Male 31691 Non-opioid analgesia Renal N/A N/A None
YC5 12+ Female 20737 Immunological products
and vaccines
Neurological,
Musculoskeletal,
Gastrointestinal, Skin
and mucous
membranes, mental
health
N/A N/A None
YC6 12+ Female 31439 Immunological products
and vaccines
Neurological, Immune,
Musculoskeletal
N/A N/A None
YC7 6–11 Female N/A Respiratory Mental health N/A N/A Respiratory
YC8 12+ Female 29831 Immunological products
and vaccines
Musculoskeletal,
Neurological
N/A N/A None
YC9 6–11 Male 22922 Immunological products
and vaccines
Gastrointestinal N/A N/A None
YC10 12+ Female 30656 Immunological products
and vaccines
Neurological,
Musculoskeletal,
Immune
N/A N/A None
YC11 0–2 Male 31508 Immunological products
and vaccines
Haematological N/A N/A None
YC12 12+ Female 30775 Immunological products
and vaccines
Immune, neurological N/A N/A None
YC13 2–6 Male 9436 Respiratory Behavioural changes N/A N/A Respiratory
YC14 2–6 Male 31612 Respiratory Behavioural changes N/A N/A Respiratory
YC15 6–11 Male 29750 Drugs used for attention
deficit disorder
Neurological N/A N/A Mental Health
YC16 12+ Male 25366 Insulin Behaviour changes,
gastrointestinal
N/A N/A Endocrine
YC17 6–11 Female 15380 Antibiotic Skin and mucous
membranes
N/A N/A None
1Age reported in year groups: 0–2; 3–5; 6–11; 12 years and over.
2Calculated using Lower Super Output Area (LSOA) 2007 ranked score data, whereby lower scores indicate greater deprivation (data for families outside England are not
reported due to incompatibility between IMD scoring systems within UK).
3Severity scores were assessed using the Hartwig scale [84] where 1 =No change in treatment with suspected drug; 2 =Drug dosing or frequency changed, without
antidote or treatment for exhibited symptoms; 3 = Required treatment, or drug administration discontinued; 4 = Resulted in patient transfer to higher level of care;
5 = Caused permanent harm to patient or significant haemodynamic instability; 6 =Directly or indirectly resulted in patient death.
doi:10.1371/journal.pone.0046022.t001
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give her paracetamol? Can she never have paracetamol or can she never have a
drug that might affect her liver?’ And they were going ‘well […] it should be fine’
but no-one was saying ‘well you can, I’ll write it down and you can have it’’’
(A12). Parents also described how they found clinicians’ commu-
nication was poorly timed and paced, with parents receiving
detailed information at times when they were anxious (e.g. when a
child was critically unwell or immediately prior to surgery) and it
was hard to absorb information, and receiving little or no
information at times when they were less anxious and better able
to absorb information. Commenting on how he/she felt over-
whelmed with information at the height of his child’s illness but
received little support when his/her daughter’s condition improved,
the parent quoted above also remarked: ‘‘All of a sudden because her
figures have gone down […] [the doctors are] out the way now’’ (A12).
Some parents were intensely critical and one parent, who was
frustrated during a visit to outpatients when clinicians could not
explain what was happening to his/her child spoke of feeling that
he/she was being lied to by clinicians: ‘‘They were fobbing me off […]
I felt like they were lying to us’’ (A5). More commonly, parents
emphasized how their concerns had been ignored or dismissed by
clinicians: ‘‘We mentioned that she’s not taking the [respiratory
medicine] anymore because of the symptoms and they didn’t comment on
it’’ (YC7); ‘‘Dismissive and wasn’t taking me very seriously’’ (A10).
While YC and ADRIC parents both voiced criticisms of
clinicians’ communication, YC parents were particularly emphatic
in their criticisms, especially when they felt clinicians had
dismissed the possibility that a child’s symptoms could be related
to a medicine with little exploration of parents’ concerns or
explanation of the reasons for ruling out an ADR: ‘‘She [GP]
literally said word for word ‘What would you like me to do?’ And I just felt
that was really dismissive’’ (YC14). The sense that their concerns had
been ignored or dismissed by clinicians left parents feeling
abandoned: ‘‘I just, just felt like nobody cared, nobody was interested and
they just wanted me to go away’’ (YC5); ‘‘I went away with all this
inadequate information […] I thought we really don’t know anything […] we
were sent home without even knowing when we were going to speak to a
professional’’ (YC1).
A striking exception to these highly critical accounts came from
the parents of children with cancer. As we outline in the next
section, these parents were almost uniformly highly positive in
their accounts of how clinicians communicated about ADRs.
Parents of children with cancer were positive about ADR
communication
Despite the life-threatening nature of the illness and the risks of
cancer treatment, parents of children with cancer felt well
supported by how clinicians communicated with them about
medicines. There was a sense from the accounts of these parents
that clinicians took ADRs seriously, were adept in communicating
about them and had well-developed systems in place for the
management of ADRs: ‘‘It’s quite scary when you first go home with this
big bag of drugs […] they said […] you can ring any time, and I rang nearly
every day’’ (A7). Parents pointed to how clinicians discussed possible
ADR symptoms and how to respond before an ADR happened, so
that parents were clear about what to look out for and what action
to take in the event of a suspected ADR. Consequently, parents felt
that clinicians communicated about medicines and ADRs in a way
that was ordered, timely and reassuring.
Implications of poor communication about suspected
ADRs
Other parents reflected on the implications of poor communi-
cation about medicines and suspected ADRs. Parents commented
on how a lack of information about potential ADRs at the time of
prescription had prevented them from being involved in decisions
about their child’s care: ‘‘If somebody had have told me that it causes the
wind […] and the constipation I probably would […] have been a bit more
forceful and say ‘well shouldn’t we give him this now?’’’ (A23); ‘‘If someone
had explained maybe […] the reactions […] we might have thought a bit more
about taking it wouldn’t we?’’ (A25). In one case, lack of information at
the time of prescription had resulted in a parent continuing to give
morphine to alleviate their child’s agitation, only to subsequently
discover that agitation could be a result of itchiness caused by
morphine: ‘‘As she kept getting more and more agitated we kept boosting it
[the morphine] […] and the more we pressed the booster[…] the itchier she
got’’ (A16).
Parents also spoke of fearing a repetition of the ADR: ‘‘Will it
happen again? […] could it happen to him, to the baby?’’ (A8), and of their
uncertainty about the implications of ADRs for their child’s future
health and use of medicines. A few parents remarked on how they
blamed themselves for what had happened because they felt:
‘‘Responsible for what goes into [their child]. I always think with these
things ‘Oh, it’s my fault’ […] Why did I let her go ahead with it?’’ (YC10).
This was a source of distress for some parents: ‘‘I was devastated […]
you think you’re doing them good and then the next minute she’s in hospital and
she could be having operations […] I just felt like crying all the time’’ (A8).
Moreover, parents either assumed that responsibility for prevent-
ing a recurrence of the ADR was theirs alone: ‘‘It’s something that I
[…] have to ask to make sure he never gets given that again’’ (A18), or they
were unclear about whether clinicians would take responsibility for
preventing a recurrence of the ADR: ‘‘I don’t know if it would be down
to me to turn round and say something or whether they have actually put
something in their notes’’ (A14); ‘‘If there was ever a situation where she didn’t
have nothing on her to say that she was allergic to morphine and something
happened to her outside […] maybe I wasn’t there […] I don’t know what
might happen’’ (A11).
In the context of poor communication, the experience of a
suspected ADR sometimes coloured parents’ views about medi-
cines, and some expressed reluctance to give certain medicines to
their child in the future. One parent became convinced that her
child’s ADR was a reaction to morphine and that this meant her
child could never have morphine again: ‘‘She’s due for this big
operation and she can’t have morphine’’ (A11). However, clinical review
of this particular case suggested that the suspected ADR was linked
to an avoidable over dosage, and that rather than avoiding
morphine altogether in future, it might be in the child’s best
interests to personalise the dose. Another parent explained how
her son was ‘‘reluctant’’ (A25) to accept painkillers, despite being in
pain because he feared a repetition of a reaction to the opioid
analgesia that he had taken, while another parent refused to allow
her child to have the final course of her vaccine: ‘‘I will categorically
say that […] I will definitely not let her have the third [human papilloma
virus] vaccine’’ (YC3).
How parents thought communication about suspected
ADRs should be handled
Reflecting parents’ accounts of poor communication about
ADRs and the resulting implications as described above, parents
wanted clinicians to help them to understand what had happened
to their child. One parent explained how the need to understand
the event was intrinsic rather than motivated by ulterior
considerations: ‘‘[It’s] not necessarily the case that everyone’s going to
jump and say, ‘Right, I’m going to sue the drug company’ and all of these sorts
of things. I think parents genuinely, who are concerned about their child’s
health, want to know what it was’’ (YC8). Another parent remarked on
how regular contact with a clinician had been reassuring: ‘‘The
doctor was back every half an hour checking on him […] Just to reassure me
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that everything was alright, it was just a reaction from it and he will be fine’’
(A18). Indeed, parents wanted discussions about what had
happened to their child to be paced and timed in a way that
would help them to absorb the information: ‘‘You just don’t think
straight when you’re there […] doctors have got to understand that […] and
maybe spend a little more time to try and explain a little bit more than they do’’
(A11).
As we also note above, parents wanted to understand what the
suspected ADR meant for their child’s future health care, and they
wanted to know about what steps would be taken to help prevent
their child suffering further ADRs to ensure s/he would receive
appropriate medicines in the future. Without exception, parents
accepted that a certain level of risk came with medicines and most
appreciated that clinicians faced uncertainty in identifying ADRs:
‘‘I think it was the antibiotics. The doctors think it is that but they can never
say it is that, because there is a possibility that it’s not that’’ (A1); ‘‘It’s just
something that, you know, just happens […] I’m sort of accepting about it’’
(YC13); ‘‘I think that ‘It’s a possibility’ is fine, erm. As long as it’s explained
clearly’’ (YC14). While parents sometimes thought clinicians were
unwilling to discuss ADRs, none blamed clinicians for their child’s
problems or said they intended to formally complain, and only one
expressed a slight ‘‘loss of trust’’ (YC8) in clinicians. However, a few
parents explained that their trust in medicines had diminished.
Alongside their wish for dialogue with clinicians about ADRs,
several parents also wanted accessible and reliable written
information about ADRs: ‘‘A leaflet about morphine […] in layman’s
terms erm you know, these side effects are rare but do look out for these’’
(A16);‘‘They should give you a little pamphlet or something to say […] look
this is what she’s got’’ (A12); ‘‘We get sheets from the pharmacy department
[…] it is something I can refer to and I would much rather that it was given
via the treatment centres than looking on the Internet because the Internet can be
a horrible place’’ (A26)
Discussion
Parents were generally disappointed with how clinicians
communicated about suspected ADRs. The majority reported
receiving little or no advance explanation about the problems that
might be associated with medicines. When information was
provided, it was in ways that parents found hard to absorb. As a
result, parents were taken by surprise when their child experienced
a suspected ADR. This turned into frustration and confusion when
clinicians were unresponsive to parents’ concerns and some
parents felt dismissed or abandoned as a result. In the absence
of explanation about what steps could be taken to prevent further
ADRs, a few parents were reluctant to give their children
medicines in the future. The key exception to these negative
accounts was parents of children with cancer, who despite their
intense fears about the illness and treatment, were generally highly
satisfied with how clinicians communicated about ADRs.
Our findings are important because as well as being a source of
avoidable parental distress, poor clinician-parent communication
about suspected ADRs may challenge parents’ confidence in
medicines and contribute to negative perceptions and misunder-
standings of medicines [69,70]. This could lead to poor adherence
in the future. We found considerable convergence among parents
about the nature of helpful communication. Their suggestions
were also similar to those reported elsewhere, particularly
regarding the process of communication, such as the importance
of the timing and pacing of information, as well as the need for
clinicians to explicitly acknowledge what had happened to the
child and help parents to understand events that they perceive to
be significant, even if the event is not clinically significant from the
perspective of clinicians [71–73]. The accounts of parents of
children being treated for cancer indicate that, despite the
complexities involved in prospectively explaining about ADRs
whilst not raising undue alarm about medicines, communication
about ADRs can be conducted in ways that parents find
informative, understandable and reassuring. However, we cannot
rule out the possibility that other factors besides communication,
such as illness beliefs specific to parents of children with cancer,
(whereby, for example, ADRs are tolerated as the ‘price’ of life-
saving treatment), might contribute to the contrasts between the
accounts of parents of children with cancer and the accounts of the
other parents. Moreover, every child with cancer will experience
ADRs as a result of their treatment and the clinicians caring for
them will have experience of children who have had severe ADRs
or died as a result of the treatment. Such experiences will
undoubtedly influence the priority that clinicians caring for
children with cancer give to ADRs and the way that they
communicate about medicines. It would be unwise or unrealistic
to suggest that clinicians in other specialties should provide parents
with the intense support that parents of children with cancer
receive. Equally, it would be nihilistic not to attempt to improve
parents’ experiences of communication about ADRs given the
problems they currently report. While clinicians are likely to focus
on prospectively briefing parents about ADRs in high-risk
situations (e.g. oncology), there are opportunities to extend such
briefings to other planned care settings where ADRs are
predictable (e.g. anaesthetics).
Parents’ wishes for a dialogue with clinicians during the
evaluation of ADRs resonate with anecdotal parental comments
reported by Bellaire et al indicating that parents prefer to see
clinicians who appreciate the significance of children’s ADRs [33].
The accounts of parents in our study also echo advice about
adverse medical events. As we note in the introduction, adverse
medical events differ from ADRs in that adverse medical events
are not necessarily attributable to the action of the medicine,
although the event may have happened during medicinal
treatment. The guidance on adverse medical events emphasises
the importance of openly acknowledging that a problem or error
has occurred and timely and clear communication [8,71,72,74–
79]. While the adverse medical events literature offers some useful
insights, we cannot automatically apply its lessons to guide
clinicians on how to communicate about ADRs in children,
particularly as the ADRs that we focussed on in this study were not
the result of an error and much of this literature has focussed on
adult patients rather than parents. Research is now needed to
explore clinicians’ views and experiences of suspected ADRs in
children. If parallels are found between clinicians’ accounts of
communicating about ADRs and the literature on their experi-
ences of communicating about AMEs, the methods used to
improve communication about AMEs [14,71,80,81] may offer
strategies for improving communication about ADRs.
One important challenge facing clinicians who communicate
about ADRs is the uncertainty involved in attributing symptoms to
medicines. Findings from other clinical contexts where uncertainty
is prominent [71,72,74–80,82] may offer further insights on
managing communication in a context of uncertainty. We found
that parents’ accounts of how they linked their child’s symptoms to
a medicine resembled the logic that clinicians use to assess the
likelihood of ADRs. Similar to this logic and the reasoning that
underpins tools for assessing ADRs [68,83], parents noted
temporal associations between a medicine’s administration and
the onset of symptoms, the receding of symptoms between doses,
and the absence of alternative explanations for symptoms.
Clinicians use similar questions to assess whether a reaction can
be attributed to a drug. The accounts of parents in this study imply
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that clinicians did not share their reasoning with parents when
assessing the likelihood of an ADR. Nevertheless, the resemblance
in the logic that parents and clinicians use in attributing symptoms
to medicines indicates some common ground between the two
parties. This common ground could be a starting point for
improving communication about ADRs. Alongside our other
findings - parents accepted that all medicines come with risks,
appreciated the uncertainty in attributing symptoms to medicines
and did not blame clinicians for suspected ADRs - we think there
is reason to be optimistic about the potential to improve clinician-
parent communication about medicines. However, research is
now needed to investigate clinicians’ perspectives on communi-
cating with parents about suspected ADRs to ensure recommen-
dations are realistic and practicable. Among other issues, this
could explore the factors that influence the timing and nature of
clinicians’ communications with parents about ADRs.
Our study had some limitations. First, we were unable to access
data on eligible ADRIC families who were not approached or did
not participate in interviews, and on YC parents who did not
respond to the MHRA’s letter. As a result, we can say little about
how interviewed parents compare to those groups. Second, before
approaching ADRIC parents we were required to consult with
their clinical teams, which may have filtered out parents whose
relationships with clinicians were strained. To address this we
sampled YC parents, as we could access them without consulting
with clinicians. However, many YC parents were health profes-
sionals themselves, or had contacts who were and their views on
communication about ADRs may be distinctive. Nevertheless, the
accounts of both ADRIC and YC parents triangulate in pointing
to the difficulties parents experience in communication about
ADRs. Finally, the interviews were conducted some time after the
child’s suspected ADR, which may have shaped their accounts in
certain ways. However, understanding the meanings that parents
take away from their experiences of ADRs is crucial in learning
how to improve their experience of ADR management and it is
these meanings that were the focus of our study.
Conclusions
Poor communication about children’s ADRs was a source of
significant difficulty for parents. Our findings will help guide
clinicians regarding what topics to cover in their discussions with
families about medicines and ADRs. At the time of prescription,
parents wanted to know the potential risks associated with
medicines. In the aftermath of a suspected ADR, they wanted to
understand what had happened to their child and in some cases
this might include explicit acknowledgment that an ADR had
possibly occurred. Parents also wanted know the potential future
implications of the suspected ADR for their child. Parents linked
their child’s symptoms to medicines in ways that resembled the
reasoning used clinically for identifying ADRs and clinicians could
possibly use this common ground as a starting point for
communicating with parents when an ADR is suspected.
However, our study’s most important contribution may lie in
providing insight for clinicians into how valuable discussions of
ADRs can be for parents.
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